Oral agent shows durable improvement in SUI patients

San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.

Related Content:

Drug TherapyFemale Urology

The antibiotic stigma associated with recurrent UTIs

Surgeons weigh in on MUS surgery for patients with stress urinary incontinence

Dr. Nickel discusses the safety of novel recurrent UTI vaccine